PubMed Health⌕ Search

Biomedical subjects

J Roliński

Publications and source records attributed to J Roliński.

At least 19 recordsLinked to original sources
PubMed2000

[Universal CD43 molecule].

CD43 is an integral cell membrane mucin appearing on hematopoietic cells in embryonic life probably on cells of vitellus bag, in embryonic and foetal liver and in foetal bone marrow. In adults CD43 occurs both on bone marrow hematopoietic stem cells as well as on peripheral mature white blood leukocytes with the exception of resting B lymphocytes. CD43 is also found on tissue macrophage, dendritic cells, smooth muscle cells, epithelium and endothelium. CD43 expression was detected on cells of leukaemias myeloid and lymphoid, lymphoma cells and metastases of solid neoplasms. Due to the elongated, twig-resembling shapes and numerous negatively charged rests of sialic acid CD43 can act in an anti-adhesive fashion e.g., disturbing ICAM-1 (CD54)--LFA-1 (CD11A/CD18) interaction. Alternatively, in certain conditions CD43 can be pro-adhesive. So, e.g., adhesion hematopoietic progenitor cells to stromal bone marrow cells partly depends on CD34-CD43 cooperation. Similarly, according to the degree of cell maturity and the kind of cell line, CD43 can induce either activation or cell apoptosis. So, bindig CD43 by specific monoclonal antibody induces activation and proliferation of T cells and also the oxidation burst of monocytes and neutrophils. On the other hand, CD43 induces apoptosis, especially in dividing progenitor hematopoietic stem cells.

Adult↗
PubMed1999

Expression of bcl-2 protein in lymphocytes of patients with laryngeal carcinoma.

The aim of this study was to evaluate the expression of bcl-2 protein in lymphocytes of the peripheral blood of patients with laryngeal carcinoma. The protein product of the proto-oncogene bcl-2 is a physiological inhibitor of apoptosis or programmed cell death. Since we believe that apoptosis is involved in the regulation of an immune response to a cancer process, we tried to show how this mechanism works in laryngeal carcinoma in comparison with normal peripheral blood lymphocytes of healthy controls. To explain the significance of this molecule's expression, we used flow cytometry to examine the expression of bcl-2 in T lymphocytes from the peripheral blood of 23 patients with laryngeal carcinoma and 20 healthy controls. Our study revealed that the expression of bcl-2 protein in T lymphocytes from the cancer patients was significantly higher than in the controls (P < 0.05). This difference in the expression of bcl-2 protein was found in both CD4 and CD8 subpopulations and was significantly higher than in the control group. In patients with laryngeal carcinoma expression of bcl-2 protein in T lymphocytes was higher in CD4 than in CD8 cells (P < 0.05). These results suggest that bcl-2 protein may interact in the regulation of apoptosis of lymphocytes, taking part in anti-cancer defence.

Adult↗
PubMed1999

Influence of low dose rIL-2 treatment on endogenous cytokine production, expression of surface IL-2R and the level of soluble IL-2R in patients with minimal residual disease.

This study was designed to investigate the immunomodulatory effect of low-dose IL-2 therapy (100 microg/day for 3 weeks) on interferon (IFN), tumor necrosis factor (TNF) production in vivo and in vitro and on the expression of IL-2Ralpha/beta and soluble form of IL-2Ralpha. Patients enrolled in the study suffered from multiple myeloma (MM), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) All of them were in remission after chemotherapy or radiotherapy. Our results indicated that IL-2 given subcutaneously at a low dose of 100 microg/day for 3 weeks induced IFN-gamma and TNF-alpha in plasma (measured 24 hrs after the last dose of IL-2) and affected the ability of blood leukocytes to produce cytokines. Production of IFN-gamma induced in vitro with PHA was enhanced, but TNF-alpha production induced by lipopolysaccharide (LPS) and virus (Newcastle Disease Virus) was depressed. The expression of both: surface IL-2R, especially beta subunit on total population of lymphocytes and NK cells, and soluble form of IL-2R, of chain were significantly enhanced after low-dose IL-2 therapy. Low dose IL-2 therapy was well tolerated by all patients, and side effects not exceeding II grade of toxicity according to WHO scale were observed. Five patients with MM relapsed 3-10 month after cessation of IL-2 therapy, but all patients with Hodgkin's and non-Hodgkin's lymphomas are still in remission (20 months of observation).

Adult↗
PubMed1999

[Expression of CD5 antigen in B and T cells from umbilical cord blood, from blood of healthy adults and patients with chronic lymphocytic B-cell leukemia (PBL-B)].

Antigen CD5 is the glycoprotein which belong to the scavenger receptor cysteine-rich family. Mainly there is on the T cells subpopulation. During fetal life B CD5+ cells are major subpopulation of B cells in the spleen, lymph nodes and there are also in the cord blood. In adult CD5+ cells are minor subpopulation (27%) of B cells from the peripheral blood. CD5 there are on chronic lymphocyte leukaemia B cells (B-CLL) also. Usually expression CD5 on B-CLL cells associated with weak or lack expression of the surface immunoglobulins and CD79 beta, CD20, CD22, CD21 (CR-2), CD35 (CR-1) antigens. It appeared interesting to compare the expression of CD5 antigen (the mean fluorescence intensity--MFI of CD5) on B cells from the cord blood, adults peripheral blood and B-CLL patients. MFI of CD5 on B and T cells were also compared in each groups. MFI of CD 19 was studied too. Lymphocytes from the cord blood (11 assays), adult peripheral blood of healthy volunteers (18 assays) and the peripheral blood of no treated patients with B-CLL (56 assays) were studied. The immunological phenotype of lymphocytes was evaluated with the monoclonal antibodies anti-CD5 and anti-CD19 by the flow cytometry method. We have demonstrated that MFI of CD5 on B cells from patients with B-CLL was strongest and weakest from normal individuals. MFI of CD5 on T cells from patients with B-CLL is stronger in comparison to healthy volunteers. MFI of CD19 is weakest on cells from patients with B-CLL and strongest in normal individuals. On the basis of the our results and other medical papers we suggest on the one hand that biology of B-CLL depend on deficit antigens specific for B cells lines on the other hand depend on overexpression of CD5 antigens on leukaemic B and T cells also.

Adult↗
PubMed1999

[CD43 in B-cell chronic lymphocytic leukemia].

CD43 (other names: sialophorin, leukosialin, sialoglycoprotein of white blood cells) is an integral cell membrane mucin. In population of peripheral B cells CD43 occurs only on activated B cells and CD5 positive B cells. These last cells create neoplasm population in patients with B-cell chronic lymphocytic leukemia (B-CLL). Anti-CD43 monoclonal antibodies are used routinely in investigations of tissue fragments in cases of non-Hodgkin's lymphoma, whereas we did not find publication on theme of CD43 expression on peripheral blood B cells in patients with B-cell chronic lymphocytic leukemia. Wherefore advisable appeared estimation CD43 expression on B-CLL cells and comparison it with expression of typical B-CLL markers--such as CD5 and CD6. Immunological phenotype of peripheral blood and bone marrow lymphocytes has been evaluated using flow cytometry (Cytoron Absolute Ortho-Diagnostic Systems) and two-color staining. Twenty six untreated patients with B-CLL were studied. Because on well-known correlations between CD43 expression and metastasis potential of tumor, patients were divided on two groups differing score of total tumor mass (score TTM). Score TTM was evaluated according to criterion of Jaksic and Vitale. Twelve patients whose TTM score was equal or lower than 9 and median lymphocytosis was 24.6 x 10(9) in microliter were included in group I. 14 patients whose TTM score was higher than 9 were included in group II. Median lymphocytosis in these patients was 152.6 x 10(9) in microliter. The median percentage of CD43+/CD19+ cells in peripheral blood was 62.6% in the group I, and 75% in the group II (p < 0.05). Median fluorescence intensity (MFI) of CD43 antigen was 87.7 in the I group comparing to 77.4 in the group II. So one observed tendency to lowering MFI during tumor growing but the difference was not significant (p = 0.25). In peripheral blood during progression of disease more clearly than CD43+ cells increased percentage of CD5+ and CD6+ cells. The median percentage of CD19+/CD5+ cells was 62.7% in the group I, 82.4% in the group II and the difference was significant (p < 0.002). The difference in the median percentages CD6+/CD19+ cell 71.8% in group I and 84.3% in the II one were also significant (p < 0.03). MFI of CD5 and also CD6 antigens did not change in course of disease. Moreover, examination of CD43 and CD5 expression in marrow additionally to blood study were performed in 12 cases (6 from group I, 2 from group II and 4 new not included). The median percentage of CD43+/CD19+ cell was 35.1% in blood and 43.7% In marrow, in contrast to these results was the median percentage of CD19+/CD5+ cell, which was higher in peripheral blood (70.4%) than in bone marrow (60.9%). The results of this study indicate that CD43 is present on peripheral blood B-CLL cells. Moreover, percentage of these cell increases during progression of disease however more weakly than percentage of CD5 and CD6 positive cells. Expression of CD43 is independent from expression CD5 and CD6 and diminishes during tumor mass increasing, what can depended from releases exocellular domains of CD43. CD43+ cell from B-CLL patients have a tendency to accumulation in tissues what is illustrated by higher percentage of CD43+ cell in bone marrow than in peripheral blood.

Adult↗
PubMed1998

[T lymphocyte subpopulations in B-cell chronic lymphocytic leukemia patients with a different percentage of CD4+ helper T cells in bone marrow].

Heterogeneity of B-cell chronic lymphocytic leukemia (B-CLL) may by partial an explanation of the ability of CLL cells to interact with the environment and it seems to be not related exclusively to cytogenetic abnormalities. For this reason T cell subpopulations were analysed in bone marrow and peripheral blood in two selected groups of B-CLL patients. These groups differed significantly in percentages of CD4+ helper T cells in bone marrow. In the first group (11 patients) percentage of CD4+ cells was higher than 9 p.c., in the second (10 patients) this percentage was equal, or lower than 2 p.c. Moreover these groups differed also in total tumor mass score (TTM-score) according to the criteria of Jaksić and Vitale. TTM-score in the first group was 9.7 in the second--22.9. In the first group CD4- cells predominated over CD8+ cytotoxic suppressor cells, as well as CD4+ CD45RO+ helper-inducer cells predominated over CD4+ CD45RA+ suppressor-inducer cells. In the second group we observed some superiority of CD8+ and CD4+ CD45RA+ cells. We can speculate that the predominance of CD4+ and CD4+ CD45RO+ cells over CD8+ and CD4+ CD45RA+ cells in bone marrow facilitate the proliferation or inhibits the apoptosis of CLL cells when the TTM-score is small. On the contrary when the TTM-score is larger, than the leukemic cells expanded in bone marrow without concomitant helper cells.

Antigens, CD↗
PubMed1998

[Expression of IL-2 receptor in peripheral blood lymphocytes and bronchoalveolar lavage fluid (BAL) in patients with sarcoidosis].

Interleukin 2 (IL-2) and its receptor (IL-2R) plays the important role in the lymphocytic alveolitis in sarcoidosis. The aim of this study was the comparative analysis of expression of IL-2 receptor subunits: alpha chain (IL-2R alpha) and beta chain (IL-2R beta) in peripheral blood and broncho-alveolar lavage fluid (BAL) in patients with sarcoidosis. We examined 18 patients (aged 23 to 47 years, 8 women and 10 men) with sarcoidosis and 5 healthy persons (the control group consisted of 2 women and 3 men, aged 25 to 39 years). The expression of IL-2R was evaluated by immunophenotyping in ORTHO Cytoron Absolute flow cytometer. Comparing the patients group to the control group, we found in BAL fluid of sarcoidosis patients statistically higher number of lymphocytes with IL-2R alpha and IL-2R beta expression (p < 0.002), when the percentage of these lymphocytes was similar in both groups. In peripheral blood of sarcoidosis patients comparing to control group, we noted higher percentage of lymphocytes with expression of IL-2R alpha and IL-2R beta (more evident difference concerned IL-2R beta) but without statistical significance. We also compared BAL fluid to peripheral blood in patients group. We found in BAL fluid lower percentage of lymphocytes with expression IL-2R beta (p < 0.02) and no significant changes in percentage and number of lymphocytes IL-2R alpha+. Our data concerning IL-2 and IL-2R suggest the activation of T lymphocytes in the lung in sarcoidosis. They present only little reflection of immunological reactions, which take place in sarcoidosis infant. The above study should be completed in future by evaluation of the other activation markers including IL-2R gamma.

Adult↗
PubMed1998

[A case of chronic B cell lymphocytic leukemia with expression of CD8 antigen on leukemic cells].

CD8 antigen is present on the surface of cytotoxic-suppressor T cells, NK cells and majority of thymocytes. Expression of CD 8 is associated with CD 3 antigen, which is a part of a T cell receptor. However, CD 8 antigen is undetectable on normal B cells. In sporadic cases of B cell-chronic lymphocytic leukaemia (B-CLL) it was found on leukaemic B cells. We report a case of B-CLL of benign course with CD19+, CD5+, CD40+, CD19+, CD20+, CD19+, CD19+HLADR+ leukaemic cells expressing CD8 antigen on CD19+ leukaemic cells. It seems that original neoplasms source was localized out of bone marrow. We suggest that the origin of the target cell for neoplasms transformation could be CD5+ B cell and CD8+ T cell gamma + delta + CD8+.

Aged↗
PubMed1997

The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia.

2-Chlorodeoxyadenosine (2-CdA) is a new antimetabolite chemotherapeutic agent active in indolent lymphoid malignancies. In this retrospective study, 69 previously untreated patients with B-cell chronic lymphocytic leukaemia (B-CLL) were treated with 2-CdA administered at a dose of 0.12 mg/kg daily in 2-h intravenous infusion for 5 consecutive days. 45 patients also received prednisone 30 mg/m2 orally each day for 5 days starting with 2-CdA courses. Patients were given 2-6 courses (mean 4.6) of 2-CdA repeated usually at monthly intervals. If a complete response was achieved, no further 2-CdA courses were administered. Guidelines for response were those developed by the NCI Sponsored Working Group. Complete response (CR) was achieved in 26 (38%) and partial response (PR) in 27 (39%) cases, giving an overall response rate of 77%. 16 patients (23%) did not respond to 2-CdA. In the subgroup of 45 patients receiving 2-CdA with prednisone, CR was obtained in 15 (33%) and PR in 20 (44%) patients giving an overall response rate of 78%. CR was achieved in 11 (46%) out of 24 patients treated only with 2-CdA and in 7 cases (29%) PR was observed, giving an objective response rate of 75%. The differences between both subgroups were not statistically significant. However, we observed a relationship between the response and the number of courses of 2-CdA given in patients receiving and those not receiving prednisone. In the subgroup receiving 2-CdA with prednisone, an earlier response to 2-CdA was observed. In this group a response was achieved in 9 (20%) patients after two courses of 2-CdA and in 18 (40%) after four courses. In the subgroup receiving only 2-CdA, 17 (71%) responses were obtained after six cycles.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1996

Interferon production by peripheral blood leukocytes of patients with acute myeloid leukemia.

The ability of peripheral blood leukocytes (PBL) of 13 selected patients with acute myeloid leukemia (AML), and of 10 healthy subjects to produce interferon (IFN) spontaneously and after in vitro induction was tested. Spontaneous IFN production was detected in supernatants of PBL cultures of healthy subjects but was not present in cultures of leukemic cells (leukocytes density 1 x 10(6) ml). After induction with Newcastle disease virus (NDV) PBL cultures from 5 patients with AML exhibited a low IFN response, while in others IFN titers were similar to controls. The IFN titers induced with lipopolysaccharide (LPS) were lower in leukemic cells than those detected in control cells. The absence or low IFN levels after induction with phytohemagglutinin (PHA) correlated with very small numbers of normal lymphocytes in blood of leukemic patients.

Adolescent↗
PubMed1996

[Phenotype of lymphocytes in bronchoalveolar lavage and peripheral blood with different clinical presentations of sarcoidosis].

The aim of this study was to investigate the relationship between the bronchoalveolar cell counts, the phenotypic characteristics of bronchoalveolar lavage and peripheral lymphocytes and the clinical manifestation of sarcoidosis. 24 patients with sarcoidosis of the lung were examined. Patients were divided into groups based on the presence and the type of clinical symptoms (patients with symptoms of Löfgren syndrome, with constitutional and respiratory symptoms and symptomless patients). The lymphocyte subtypes were analysed using the panel of monoclonal antibodies Simultest IMK Plus with the flow cytometry (Orto Cytoron Absolute). The highest ratio CD4/CD8 in BALF was found in patients with symptoms of Löfgren Syndrome (mean 11.4), the lowest in symptomless patients (mean 4.5). The bronchoalveolar cell count and the percentages of phenotypes of peripheral blood lymphocytes did not differ significantly between the groups of patients. The bronchoalveolar lavage performed in patients with sarcoidosis indicates various intensity of alveolitis dependent on the clinical manifestation.

Adult↗
PubMed1995

[Spontaneous and induced production of tumor necrosis factor (TNF alpha) by peripheral blood leukocytes in patients with acute leukemia type M 4 and M5 according to FAB].

Tumor necrosis factor (TNF) is a cytokine with pleiotropic biological activity. We have undertaken the present study to evaluate a possible ability of peripheral blood cells of healthy subjects and patients with acute monocytic leukemia to produce TNF alpha. We studied 17 leukemia patients and 8 control subjects. Spontaneous production of TNF alpha induced by LPS and Newcastle disease virus (NDV) were determined in blood cell cultures. Leukemic cells released markedly higher level of TNF alpha than control cells cultured in vitro in contrast to control cells producing TNF spontaneously. It seems that leukemic cells can produce TNF in response to very small amount of LPS; however, we cannot exclude that spontaneous TNF may be involved in autocrine regulation of proliferation and differentiation of bone marrow monocyte precursors.

Adult↗
PubMed1995

[Interleukin 2 receptor (Il-2): structure and function].

Interleukin 2 and its receptor play a crucial role in the growth and differentiation of many cells such as lymphocytes T and B, NK cells, macrophages and monocytes. Il-2 receptor (Il-2R) is involved in Il-2 induced cellular signalling. We discuss the Il-2R structure, function of three distinct subunits and the complex pathways that link the cell surface receptor to the nuclear proto-oncogene production.

Cell Differentiation↗
PubMed1994

[An attempt at differentiating between medullary and extramedullary derived B-cell chronic lymphocytic leukemia].

A comparative research on lymphocyte immunological phenotypes in peripheral blood and bone marrow was carried out on 14 patients with B-cell chronic lymphocytic leukaemia. Three types of B cell markers were estimated: 1-light chains (lambda or kappa) on the surface of cells, 2-CD5 antigen, 3-capability of forming mouse erythrocyte rosettes (MER); the last two markers are mostly characteristic of leukaemic cells. The patients were divided into 3 groups according to the localisation of the main mass of tumorous cells: group I-the patients, whose clinical picture was dominated by the infiltration of lymphoid structures of the abdominal cavity and/or with massive infiltration of peripheral lymph nodes; group II-the patients, whose clinical picture was dominated by the infiltration of bone marrow; group III-the intermediate-patients with large mass of tumor in lymphoid structures and with bone marrow insufficiency symptoms. In most of the patients of group I, the percentage of CD5+ cells in peripheral blood was higher than the one in bone marrow (arithmetic means were 38.5% for blood and 26.7% for marrow). It was the reverse in group II (the means were 44.8% for blood and 64.3% for marrow, P < 0.01). The percentage in group III was similar to that of group I (the means-48% for blood and 29.25% for marrow). No correlation between the percentage of CD5+ and MER+ cells was found in respective groups of the patients although the last marker behaved similarly to CD5. The results obtained suggest that while estimating percentages of CD5+ cells in peripheral blood and bone marrow, one can differentiate between chronic lymphocytic leukaemia (with domination of CD5+ cells in bone marrow) and leukaemic phase of small lymphocyte lymphoma (with domination of CD5+ cells in peripheral blood).

Adult↗